Comparing SG&A Expenses: Pfizer Inc. vs Agios Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Pfizer Inc. and Agios Pharmaceuticals, Inc. from 2014 to 2023.

Pfizer Inc.: A Steady Giant

Pfizer, a global pharmaceutical leader, consistently reported SG&A expenses around $14 billion annually. Despite fluctuations, their expenses remained relatively stable, reflecting their robust market position and efficient cost management.

Agios Pharmaceuticals, Inc.: A Growth Story

In contrast, Agios Pharmaceuticals, a smaller biotech firm, saw a significant rise in SG&A expenses, increasing by over 500% from 2014 to 2020. This growth underscores their aggressive expansion and investment in research and development.

Insights and Trends

While Pfizer's expenses highlight stability, Agios's trajectory reflects a dynamic growth strategy. This comparison offers valuable insights into the strategic priorities of these pharmaceutical entities.